Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Published version of a preprint
The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
Purpose: We evaluated the predictive and prognostic value of circulating tumor DNA (ctDNA) in patients with Ewing sarcoma (EWS) treated in the EWING2008 trial. Experimental Design: Plasma samples from 102 patients with EWS enrolled in the EWING2008 trial were obtained before and during induction chemotherapy. Genomic EWSR1 fusion sequence spanning primers and probes were used for highly specific and sensitive quantification of the levels of ctDNA by digital droplet PCR. ctDNA levels were correlated to established clinical risk factors and outcome parameters. Results: Pretreatment ctDNA copy numbers were correlated with event-free and overall survival. The reduction in ctDNA levels below the detection limit was observed in most cases after only two blocks of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) induction chemotherapy. The persistence of ctDNA after two VIDE blocks was a strong predictor of poor outcomes. ctDNA levels correlated well with most established clinical risk factors; an inverse correlation was found only for the histologic response to induction therapy. ctDNA levels did not provide simple representations of tumor volume, but integrated information from various tumor characteristics represented an independent EWS tumor marker with predictive and prognostic value. Conclusions: ctDNA copy number in the plasma of patients with EWS is a quantifiable parameter for early risk stratification and can be used as a dynamic noninvasive biomarker for early prediction of treatment response and outcome of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date have demonstrated the prognostic impact of ctDNA in Ewing sarcoma (EWS), rhabdomyosarcoma, Wilms tumor (WT), and osteosarcoma (OS).14–18”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [18]
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907 · cited 1×
“EWSR1-FLI1 and EWSR1-ERG are the two most common fusion genes, occurring in 85% to 90% and approximately 10%, respectively (14, 15).”
BackgroundTie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Application of Cell-free DNA Analysis to Cancer Treatment
Corcoran, R. B., & Chabner, B. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706174 · Cited by 950
Grünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Self-citation
Cited by
Artificial intelligence-based radiomics in bone tumors: Technical advances and clinical application
Meng, Y., Yang, Y., Hu, M., Zhang, Z., & Zhou, C. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.07.003 · Cited by 83
UK guidelines for the management of bone sarcomas
Gerrand, C., Amary, F. M., Anwar, H. A., Brennan, B. M. D., Dileo, P., Kalkat, M. S., McCabe, M. G., McCullough, A. L., Parry, M., Patel, A., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02868-4 · Cited by 82
Shulman, D. S., Whittle, S. B., Surdez, D., Bailey, K. M., de Álava, E., Yustein, J. T., Shlien, A., Hayashi, M., Bishop, A. J. R., Crompton, B. D., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00307-2 · Cited by 62
Abbou, S., Klega, K., Tsuji, J., Tanhaemami, M., Hall, D., Barkauskas, D. A., Krailo, M. D., Cibulskis, C., Nag, A., Thorner, A. R., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00409 · Cited by 44
“One recent report in Ewing sarcoma, another translocation-driven sarcoma, demonstrated that detectable levels of ctDNA present after two cycles of therapy were associated with relapse.(35) Future studies will be needed to determine whether changes in ctDNA during therapy are prognostic in RMS or whether measurements o…”
BackgroundMadanat-Harjuoja, L. M., Renfro, L. A., Klega, K., Tornwall, B., Thorner, A. R., Nag, A., Dix, D., Dome, J. S., Diller, L. R., Fernandez, C. V., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00098 · Cited by 41
Metadata
- Authors
- Krumbholz, M., Eiblwieser, J., Ranft, A., Zierk, J., Schmidkonz, C., Stütz, A. M., Peneder, P., Tomazou, E. M., Agaimy, A., Bäuerle, T., Hartmann, W., Dirksen, U., & Metzler, M.
- Affiliations
- Universitätsklinikum Erlangen (DE)
- Essen University Hospital (DE)
- St. Anna Children's Cancer Research Institute (AT)
- University Hospital Münster (DE)
- Corresponding author
- Krumbholz, Manuela
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2021-08-23
- Volume
- 27
- Issue
- 21
- Pages
- 5922-5930
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3193636501
- Cited by
- 39
- References
- 43
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 5 · 2023: 9 · 2022: 7
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- EURO EWING Consortium (602856)
- German Cancer Aid (108128, 70113419, 70112018)
- EraNet consortium PROspective VAlidation of Biomarkers in Ewing Sarcoma (01KT1310)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- Ewing sarcoma, circulating tumor DNA, ctDNA quantification, fusion transcripts, droplet digital PCR, treatment response prediction, risk stratification, prognostic factors, event-free survival, overall survival, non-invasive biomarkers
- MeSH terms
- Circulating Tumor DNA, Adolescent, Adult, Antineoplastic Agents, Bone Neoplasms, Child, Child, Preschool, Female, Humans, Male, Predictive Value of Tests, Prognosis, Sarcoma, Ewing, Time Factors, Translocation, Genetic, Treatment Outcome, Risk Assessment, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-1324
- The paper
- Krumbholz, M., Eiblwieser, J., Ranft, A., Zierk, J., Schmidkonz, C., Stütz, A. M., Peneder, P., Tomazou, E. M., Agaimy, A., Bäuerle, T., Hartmann, W., Dirksen, U., & Metzler, M. (2021). Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-1324
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.